Dinutuximab

Products

Dinutuximab was approved in the United States and the EU in 2015 as a concentrate for the preparation of an infusion solution (Unituxin). It has not yet been registered in many countries.

Structure and properties

Dinutuximab is a chimeric monoclonal antibody (human/mouse).

Effects

Dinutuximab (ATC L01XC16) has cytotoxic properties. It binds to ganglioside GD2, which is expressed primarily on the surface of neuroblastoma cells. The binding elicits a cell-toxic response from the immune system.

Indications

For the treatment of high-risk neuroblastoma.

Dosage

According to the SmPC. The drug is administered as an intravenous infusion.

Adverse effects

The most common possible adverse effects include hypotension, pain, hypersensitivity, fever, and hives.